Suchergebnisse - "Remes, Kari"

PubPharm (77)

31

Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients

enthalten in: British journal of haematology | 2013

von Silvennoinen, R. | Kairisto, V. | Pelliniemi, T. | +12

32

Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients

enthalten in: British journal of haematology | 2013

von Silvennoinen, R. | Kairisto, V. | Pelliniemi, T. | +12

33

Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome) : A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2012

von Cwynarski, K. | van Biezen, A. | de Wreede, L. | +12

CommentIn: Acta Haematol. 2016;136(4):244-255. - PMID 27802434

34

Autologous and Allogeneic Stem-Cell Transplantation for Transformed Chronic Lymphocytic Leukemia (Richter's Syndrome): A Retrospective Analysis From the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

enthalten in: Journal of clinical oncology / Englische Ausgabe | 2012

von Cwynarski, K. | van Biezen, A. | de Wreede, L. | +12

35

Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma

enthalten in: Hematology reports | 2012

von Salmenniemi, U. | Remes, K.

36

BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib : more heterogeneous than just ABL kinase domain point mutations?

enthalten in: Medical oncology (Northwood, London, England) | 2012

von Gruber, F. | Lundán, T. | Goll, R. | +8

37

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

enthalten in: Blood | 2011

von Simonsson, B. | Gedde-Dahl, T. | Markevärn, B. | +26

CommentIn: Int J Hematol. 2012 Jul;96(1):142-3. - PMID 22639055

38

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

enthalten in: Blood | 2011

von Simonsson, B. | Gedde-Dahl, T. | Markevärn, B. | +25

39

Stem cell transplantation in myelofibrosis

enthalten in: Duodecim; laaketieteellinen aikakauskirja | 2011

von Toivari, A. | Itälä-Remes, M. | Kauppila, M. | +3

40

BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?

enthalten in: Medical oncology | 2011

von Gruber, F. | Lundán, T. | Goll, R. | +8